Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00329329|
Recruitment Status : Terminated (Sponsor decided to discontinue study drug development)
First Posted : May 24, 2006
Last Update Posted : March 23, 2012
|Condition or disease||Intervention/treatment||Phase|
|Malignancies||Drug: satraplatin and capecitabine||Phase 1|
This is a single center, open-label, non-randomized, Phase I dose finding study of the investigational, oral cytotoxic drug, satraplatin in combination with capecitabine in patients with advanced solid tumors for whom curative therapy is not available. Please refer to the Eligibility Criteria below for key inclusion and exclusion criteria.
PURPOSE: The purpose of this trial is to determine a tolerable dose and schedule for the combination of satraplatin and docetaxel when given to patients with advanced solid tumors.
WHAT IS SATRAPLATIN: Satraplatin is an oral, investigational anticancer drug that is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase 1 Study of the Oral Platinum Agent Satraplatin in Combination With Capecitabine for the Treatment of Patients With Advanced Solid Malignancies|
|Study Start Date :||May 2006|
|Actual Primary Completion Date :||January 2009|
|Actual Study Completion Date :||February 2009|
Drug: satraplatin and capecitabine
- MTD [ Time Frame: 2007 ]
- Safety [ Time Frame: 2007 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00329329
|United States, Illinois|
|Northwestern University Medical Center|
|Chicago, Illinois, United States, 60611|
|Principal Investigator:||William Gradishar, MD||Northwestern University Medical Center|